Purpose In the last decade, the research community has focused on defining reliable
biomarkers for the early detection of Alzheimer's disease (AD) pathology. In 2017, the …

This article presents recommendations, based on the Grading of Recommendations,
Assessment, Development, and Evaluation method, for the clinical application of …

Background Brain amyloidosis does not invariably predict dementia. We hypothesized that
high soluble 42-amino acid β amyloid (Aβ42) peptide levels are associated with normal …

BACKGROUND Low cerebrospinal fluid (CSF) amyloid-β 1–42 (Aβ 1–42) concentrations
indicate amyloid plaque accumulation in the brain, a pathological hallmark of Alzheimer …

Background In recent years, longitudinal studies of Alzheimer's disease (AD) have been
successively concluded. Our aim is to determine the efficacy of amyloid‐β (Aβ) PET in …

The aim of this study was to assess the agreement between data on cerebral amyloidosis,
derived using Pittsburgh compound B positron emission tomography and (i) multi-laboratory …

We studied whether electroencephalography (EEG)-derived measures of brain oscillatory
activity are related to clinical progression in nondemented, amyloid positive subjects. We …

Alzheimer's disease (AD) is characterized by amyloid plaques and tau pathology
(neurofibrillary tangles and neuropil threads). Amyloid plaques are primarily composed of …

During this decade, breakthrough conceptual shifts have commenced to emerge in the field
of Alzheimer's disease (AD) recognizing risk factors and the non-linear dynamic continuum …

Background: Evidence suggests that the concordance between amyloid-PET and
cerebrospinal fluid (CSF) amyloid-ß (Aß) increases when the CSF Aß1–42/Aß1–40 ratio is …